摘要
目的观察盐酸埃克替尼交替化疗治疗晚期非小细胞肺癌EGFR未知患者的近期疗效及不良反应。方法将本院肿瘤科2012年3月至2013年5月收治EGFR未知晚期非小细胞肺癌患者42例分为治疗组与对照组,均予吉西他滨联合顺铂方案化疗,治疗组加用口服盐酸埃克替尼125mg,3次/d,D15-28,两周期后即按RECIST1.1标准评价疗效,稳定及以上者均视为有效,观察近期疗效、KPS评分改善率、毒副反应等指标。结果 42例患者均治疗2周期后评价,其中治疗组完全缓解(CR)2例,部分缓解(PR)11例,疾病稳定(SD)4例,疾病进展(PD)2例,客观缓解率(ORR)为68.42%,疾病控制率(DCR)89.47%;对照组完全缓解(CR)1例,部分缓解(PR)7例,疾病稳定(SD)9例,疾病进展(PD)6例,客观缓解率(ORR)为34.78%,疾病控制率(DCR)65.21%。结果显示治疗组近期治疗效果优于对照组,提高患者生存质量,毒副反应骨髓抑制、恶心呕吐及腹泻反应与化疗相同,而口服埃克替尼后增加了皮疹反应,但因反应较轻,均能耐受。结论分子靶向药物盐酸埃克替尼交替化疗对晚期NSCLC有显著疗效,提高了疾病控制率及生存质量。
Objective The recent curative effect and adverse reaction observation of icotinib alternating chemotherapy in the treatment of advanced non small cell lung cancer patients with EGFR unknown. Methods The Institute of oncology in 2012 March to 2013 May were unknown in EGFR patients with advanced non small cell lung cancer 42 cases were divided intotreat-ment group and control group,were treated with gemcitabine combined with cisplatin chemotherapy,treatment group was treated with oral icotinib 125mg,3 times/day,D15-28,after two cycles according to RECIST 1.1 standard evaluation of curative effect,sta-ble and above are considered to be effective,the recent observation of curative effect,KPS score improvement rate,toxicity index. Results 42 patients were evaluated after 2 cycles treatment,the treatment group（CR） and 2 cases of complete remission,partial re-mission （PR） 11 cases,stable disease （SD） in 4 cases,progression of disease （PD） in 2 cases,the objective response rate （ORR） was 68.42%,disease control rate （DCR） control group 89.47%;complete remission （CR） 1 cases,partial remission （PR） 7 cases,stable disease （SD） in 9 cases,progression of disease （PD） in 6 cases,the objective response rate （ORR） was 34.78%,disease control rate （DCR） of 65.21%;the results showed that the treatment group is better than control group in recent curative effect ,improve the pa-tients quality of life adverse reactions,bone marrow suppression,nausea,vomiting and diarrhea and chemotherapy response in the same,and oral icotinibincreased skin rashes,but because the reaction is mild,tolerated the. Conclusion Molecular targeted drugs of icotinib alternating chemotherapy has significant effect on advanced NSCLC,improved disease control rate and survivalquality.
出处
《江西医药》
CAS
2015年第4期298-301,共4页
Jiangxi Medical Journal
关键词
盐酸埃克替尼
非小细胞肺癌
化疗
临床观察
EGFR
Icotinib
Non-small-cell-lung cancer
EGFR
Chemotherapy
Clinical observation
